Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors

[1] Travis WD(2010)Advances in neuroendocrine lung tumors Ann Oncol 21 vii65-vii71

[2] Rekhtman N(2010)Neuroendocrine tumors of the lung: an update Arch Pathol Lab Med 134 1628-1638

[3] Bertino EM(2009)Pulmonary neuroendocrine/carcinoid tumors: a review article Cancer 115 4434-4441

[4] Confer PD(2012)Emerging drugs for small cell lung cancer - an update Expert Opin Emerg Drugs 17 31-36

[5] Colonna JE(2015)Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway Trends Mol Med 21 24-33

[6] Ross P(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 563-567

[7] Otterson GA(2016)Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients Br J Cancer 115 1186-1192

[8] Metro G(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-144

[9] Duranti S(2017)Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials ESMO Open 2 e000236-562

[10] Fischer MJ(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-190

[1] Travis WD(2010)Advances in neuroendocrine lung tumors Ann Oncol 21 vii65-vii71

[2] Rekhtman N(2010)Neuroendocrine tumors of the lung: an update Arch Pathol Lab Med 134 1628-1638

[3] Bertino EM(2009)Pulmonary neuroendocrine/carcinoid tumors: a review article Cancer 115 4434-4441

[4] Confer PD(2012)Emerging drugs for small cell lung cancer - an update Expert Opin Emerg Drugs 17 31-36

[5] Colonna JE(2015)Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway Trends Mol Med 21 24-33

[6] Ross P(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 563-567

[7] Otterson GA(2016)Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients Br J Cancer 115 1186-1192

[8] Metro G(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-144

[9] Duranti S(2017)Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials ESMO Open 2 e000236-562

[10] Fischer MJ(2014)MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer Nature 515 558-190